Approach to decongestion therapy in patients with acute decompensated heart failure: the echocardiography guided

Alper Karakus1, Berat Uguz2

  • 1Department of Cardiology, Besni State Hospital, Adıyaman, Turkey.

Kardiologiia
|March 15, 2021
PubMed

Insights

The E/Ea×Sa index guided diuretic therapy offers a safer and more effective treatment strategy for acute decompensated heart failure with reduced ejection fraction patients. This echocardiographic method improved NT pro-BNP levels and reduced dyspnea compared to conventional urine output monitoring.

Area of Science:

  • Cardiology
  • Echocardiography
  • Heart Failure Management

Background:

  • Left ventricular filling pressure is crucial in managing heart failure.
  • Current diuretic therapy guidance relies on parameters like urine output.
  • The E/Ea×Sa index is an echocardiographic parameter for assessing filling pressures.

Purpose of the Study:

  • To evaluate the safety and efficacy of diuretic therapy guided by the E/Ea×Sa index.
  • To compare E/Ea×Sa index guided therapy with conventional urine output guided therapy in acute decompensated heart failure with reduced ejection fraction (HFrEF).

Main Methods:

  • A cross-sectional study involving hospitalized HFrEF patients in acute decompensation.
  • Patients were randomized 1:1 to either E/Ea×Sa index guided or urine output guided diuretic therapy.
  • Diuretic dose was adjusted to achieve a 20% reduction in the E/Ea×Sa index.

Main Results:

  • E/Ea×Sa index guided therapy resulted in significantly lower NT pro-BNP levels within 72 hours (p=0.036).
  • Patients in the E/Ea×Sa index group reported significantly better dyspnea scores (p=0.04).
  • Both groups showed similar outcomes in weight loss, eGFR, renal function, and electrolyte balance.

Conclusions:

  • Echocardiographic E/Ea×Sa index guidance is a safe strategy for effective diuretic response in acute decompensated HFrEF.
  • This method shows promise for selected HFrEF patients requiring diuretic therapy.
  • Further consideration for this guided therapy in specific patient subgroups is warranted.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
77
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
97
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
113
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
657
Imaging Studies for Cardiovascular System I:Echocardiography01:17

Imaging Studies for Cardiovascular System I:Echocardiography

Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
567
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
596